PET/MRI can be a boon for pediatric cancer patients

Young pediatric patients may benefit from FDG-PET/MRI for staging and clinically evaluating oncologic disorders, given the hybrid modality's superior soft-tissue contrast and significantly lower radiation dose, according to a study published online in Investigative Radiology.

German researchers found FDG-PET/MRI to be at least as good as FDG-PET/CT for evaluating pediatric cancer patients younger than 6 years, potentially changing the treatment plan for almost half of the study's cohort. Read more.